Contact SCGE




Clinical Trial Report

Gene Therapy Trial Report

Summary

Safety Study of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase to Treat Pompe Disease


NCTID NCT00976352 (View at clinicaltrials.gov)
Description
Development Status Inactive
Indication Glycogen Storage Disease Type 2 (Pompe Disease)
Disease Ontology Term DOID:2752
Compound Name AAV1-CMV-hGAA
Sponsor University of Florida
Funder Type Other
Recruitment Status
Completed
Enrollment Count 9
Results Posted View Results

Therapy Information


Target Gene/Variant GAA
Therapy Type Gene transfer
Therapy Route In-vivo
Mechanism of Action Functional gene replacement
Route of Administration Intramuscular (diaphragm)
Drug Product Type Viral vector
Target Tissue/Cell
Delivery System Viral transduction
Vector Type AAV2/1
Editor Type none
Dose 1 1E12 vg (n=3)
Dose 2 5E12 vg (n=6)
Dose 3
Dose 4
Dose 5

Study Record Dates


Current Stage Phase1, Phase2
Submit Date 2009-07-13
Completion Date 2015-12
Last Update 2018-09-14

Participation Criteria


Eligible Age 2 Years - 18 Years
Standard Ages Child, Adult
Sexes Eligible for Study ALL

Locations


No.of Trial Sites 1
Locations United States

Regulatory Information


Has US IND True
FDA Designations
Recent Updates Sponsors of this trial redesigned the drug product by changing the capsid (AAV2/1 -> AAV2/9) and promoter (CMV->DES), and site of administration (diaphragm -> tibialis anterior), updated trial record is NCT02240407

Resources/Links